- Home
- FHN vs TGTX Comparison
FHN vs TGTX Comparison
Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- TGTX
- Stock Information
- Founded
- FHN 1864
- TGTX 1993
- Country
- FHN United States
- TGTX United States
- Employees
- FHN N/A
- TGTX N/A
- Industry
- FHN Major Banks
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- TGTX Health Care
- Exchange
- FHN Nasdaq
- TGTX Nasdaq
- Market Cap
- FHN 11.0B
- TGTX 4.2B
- IPO Year
- FHN N/A
- TGTX 1995
- Fundamental
- Price
- FHN $22.69
- TGTX $32.04
- Analyst Decision
- FHN Buy
- TGTX Strong Buy
- Analyst Count
- FHN 17
- TGTX 5
- Target Price
- FHN $23.32
- TGTX $45.00
- AVG Volume (30 Days)
- FHN 11.4M
- TGTX 2.1M
- Earning Date
- FHN 10-15-2025
- TGTX 11-03-2025
- Dividend Yield
- FHN 2.66%
- TGTX N/A
- EPS Growth
- FHN 28.04
- TGTX N/A
- EPS
- FHN 1.55
- TGTX 0.36
- Revenue
- FHN $3,083,000,000.00
- TGTX $454,069,000.00
- Revenue This Year
- FHN $10.95
- TGTX $82.58
- Revenue Next Year
- FHN $3.68
- TGTX $44.99
- P/E Ratio
- FHN $14.58
- TGTX $88.81
- Revenue Growth
- FHN 4.62
- TGTX 30.96
- 52 Week Low
- FHN $14.83
- TGTX $21.16
- 52 Week High
- FHN $23.08
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- FHN 55.94
- TGTX 56.50
- Support Level
- FHN $21.94
- TGTX $31.29
- Resistance Level
- FHN $23.08
- TGTX $32.56
- Average True Range (ATR)
- FHN 0.47
- TGTX 1.15
- MACD
- FHN -0.04
- TGTX 0.32
- Stochastic Oscillator
- FHN 65.35
- TGTX 73.48
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.